DFTX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Definium Therapeutics, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 43.52 USD
0.8% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 76.2% above the Trend Line and sits at 86.0% of its 52-week range. The latest completed week returned 0.8%, after a -1.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 44/100 conviction, while the latest news-sentiment score is 59/100. Near-term considerations: volume confirmation is below normal.

Setup score 64 out of 100
Latest Close 43.52 USD 31 Jul 2026
1W Return 0.8% latest completed week
4W Return -1.5% short-term follow-through
12W Return 97.4% quarterly tape
Trend Breadth 100.0% 52 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 55-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 9 reversal markers appear in the recent smart-money tape.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.8% Latest completed week; four-week move -1.5%. Indicator stack 100/70 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 44/100 conviction; expected move 23.4%. News sentiment 59/100 63 relevant articles in the latest sentiment read. Event risk 30 Jul Latest stored earnings date was 30 Jul 2026.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 76.2% above the Trend Line and sits at 86.0% of its 52-week range. The latest completed week returned 0.8%, after a -1.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9712-week average 0.92

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.97Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers99 reversal markers

No recent accumulation markers. 9 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -1.5% over four weeks, 97.4% over 12 weeks, and 415.6% over one year. The current trend has remained active for 55 consecutive weeks.

Performance by holding period

1W0.8%
4W-1.5%
12W97.4%
26W157.8%
52W415.6%
Active trend streak55 weeks
Active weeks in one year52
Trend breadth100.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.24Latest activity-pressure read.
Pressure change-24.5%Four-week change in activity pressure.
Leadership114.49Latest relative-leadership reading.
RS change-18.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength64/100Blend of value, momentum, and quality. Underlying universe rank 37; rank 1 is best.
Value56/100Relative valuation strength. Underlying universe rank 45; rank 1 is best.
Quality55/100Profitability and accounting quality. Underlying universe rank 46; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-2.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-293.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-4.5%
Net share repurchases relative to market value.
Shareholder yield
-4.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

DFTX shows bullish options pressure with a 44/100 conviction score, put-call volume ratio of 0.68, expected move of 23.4%, and Sharemaestro trend signal active.

Conviction44/100
Expected move23.4%
Put/call volume0.68
Pressure26
Speculation7
Volatility96
Trend agreement84
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment59/100

Weighted news tone is neutral across 63 relevant articles.

27 positive · 35 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings30 JulLatest stored earnings date was 30 Jul 2026.
Options expected move23.4%Nearest-chain priced movement where available.
52-week drawdown-11.5%Distance below the 52-week high.
13-week volatility22.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+83.6%Week of 26 Jun.
Worst week-6.8%Week of 13 Feb.
Latest week+0.8%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains7
Flat weeks0
Modest losses7
Sharp losses3
Recent vol22.5%13-week weekly-return volatility.
Base vol13.7%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew9.5% / -5.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape63/100

Trend, activity pressure, participation, and risk combine to a 63/100 tape read.

 Indicator analysis83/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.97; 9 reversal markers Factors57/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 82; Small Cap Core rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options67/100

DFTX shows bullish options pressure with a 44/100 conviction score, put-call volume ratio of 0.68, expected move of 23.4%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 23.4% Sentiment59/100

Weighted news tone is neutral across 63 relevant articles.

Will Strong Phase 3 Depression Data and Q2 Review Webcast Change Definium Therapeutics' (DFTX) Narrative Insiders50/100

No recent insider transaction evidence is stored.

 Earnings30 Jul

Latest stored earnings date was 30 Jul 2026.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202643.52 USD0.8%24.71 USD10.61 USD1.24114.499.0MOn
24 Jul 202643.17 USD-2.5%23.71 USD10.36 USD1.51120.845.9MOn
17 Jul 202644.29 USD-5.9%22.71 USD10.11 USD1.85130.059.6MOn
10 Jul 202647.07 USD6.5%21.65 USD9.86 USD1.72142.3712.9MOn
3 Jul 202644.19 USD-1.7%20.50 USD9.58 USD1.64140.3414.5MOn
26 Jun 202644.95 USD83.6%19.44 USD9.32 USD1.51155.9458.7MOn
19 Jun 202624.48 USD-1.1%18.36 USD9.06 USD1.3038.656.8MOn
12 Jun 202624.75 USD5.1%17.90 USD8.92 USD1.4246.2412.3MOn
5 Jun 202623.55 USD-2.6%17.46 USD8.79 USD1.2144.8213.1MOn
29 May 202624.19 USD7.5%17.06 USD8.66 USD1.2344.308.6MOn
22 May 202622.50 USD7.2%16.73 USD8.53 USD1.2140.337.9MOn
15 May 202620.99 USD-4.8%16.39 USD8.40 USD1.4434.466.5MOn
8 May 202622.05 USD1.6%16.15 USD8.29 USD1.8042.917.6MOn
1 May 202621.70 USD-3.5%15.81 USD8.17 USD1.8550.837.7MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.